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Clinicians commonly use inhaled ribavirin to treat HSCT re-
cipients with Respiratory Syncytial Virus (RSV); however,
limited data exist to support this therapy. We evaluated 349
consecutive patients transplanted between June, 2008 and
December, 2013. Eighteen (5.2%) pediatric and young adult
patients (6 months to 25 years of age) developed an RSV
infection. Fifteen (83%) patients presented with an upper
respiratory tract infection (URTI) identiﬁed a median of 151
(range3e621) days post-HSCTand3 (17%) presentedwith, or
progressed to, a lower respiratory tract infection (LRTI)
identiﬁed amedian of 33 (range 10e117) days post-HSCT. All
3 patients with LRTI had signiﬁcant co-infections while 2/3
were less than 1 year of age at the time RSV was identiﬁed.
Fifteen (83%, 13/15 with URTI and 2/3 with LRTI) were still
receiving immunosuppressants. All 18 patients were lym-
phopenic (median 280, range 0 e 2120). Eleven of 15 (73%)
patientswith URTI and all 3 patientswith LRTIwere receiving
routine intravenous immunoglobulin (IVIG) supplementation
every 1-2 weeks to maintain normal IGG levels after HSCT.
RSV-targeted treatment included an increase in frequency or
additional IVIG administration for 4/15 and 3/3 URTI and LRTI
patients, respectively. ThreeURTI patients and 2 LRTI patients
receiving IVIG were also given palivizumab. No patients
received inhaled ribavirin or died as a direct result of RSV
infection suggesting that ribavirin may not be an essential
component of RSV treatment in pediatric HSCT recipients.295
A Pilot Trial of Unrelated Cord Blood Transplantation
(UCBT) and Unmatched Human Placental Derived Stem
Cells (HPDSC) in Children and Young Adults with
Malignant and Non-Malignant Disease
Mona Elmacken 1, Michael A. Pulsipher 2, Qiuhu Shi 3,
Roger Giller 4, Theodore B. Moore 5, Lauren Harrison 1,
Erin Morris 1, Olga Militano 1, Janet Ayello 1,
Mildred Semidei-Pomales 1, Sandra Fabricatore 1,
Xiaokui Zhang 6, Jodi Gurney 6, Jessica Hochberg 1,
Lee-Ann Baxter Lowe 7, Mitchell S. Cairo 1,8,9,10,11. 1 Pediatrics,
New York Medical College, Valhalla, NY; 2Huntsman Cancer
Institute, University of Utah School of Medicine, Salt Lake City,
UT; 3 Biostatistics, New York Medical College, Valhalla, NY;
4 Pediatrics, The Children’s Hospital, Denver, University of
Colorado School of Medicine, Aurora, CO; 5 Pediatrics, DavidFigure 1. (A) Participating Institutions in this multicenter HPDSCGeffen School of Medicine at UCLA, Los Angeles, CA; 6 Celgene
Cellular Therapeutics, Warren, NJ; 7 Pediatrics, Children’s
Hospital of Los Angeles, Los Angeles, CA; 8Microbiology and
Immunology, New York Medical College, Valhalla, NY;
9 Pathology, New York Medical College, Valhalla, NY; 10 Cell
Biology and Anatomy, New York Medical College, Valhalla, NY;
11Medicine, New York Medical College, Valhalla, NY
Background: Initial studies by our group and others
demonstrated that myeloablative conditioning (MAC) fol-
lowed by UCBT (matched at 4-6/6 HLA loci) in children with
malignant and non-malignant diseases was safe and well
tolerated (Wagner/Cairo et al, Blood, 1996; Kurtzberg et al,
NEJM,1996). However, there is a low concentration of CD34+
hematopoietic progenitor cells (HPC) in banked CB (Cairo/
Kurtzberg et al, Transfusion, 2005), resulting in delayed he-
matopoietic reconstitution and 10-20% incidence of graft
failure resulting in increased transplant-related mortality
(TRM) (Cairo et al, Blood,1997; Satwani/Cairo et al,
BBMT,2013). More recently, Robin et al have demonstrated
human stem and progenitor cells were detected in placental
tissue (Robin et al, Cell Stem Cell, 2009). Celgene Cellular
Therapeutics (CCT) has developed a proprietary, sterile
closed perfusion process for the collection of Human
Placental Derived Stem Cells (HPDSC) from full term pla-
centas. HPDSC are rich in HPCs, HPC CFU forming capabilities,
low in HLA Class I and II expression and enhance in-vivo
engraftment when combined with UCBT in NOD-SCID ani-
mals (Mendez-Ferrer et al, Nature,2010).
Objectives: To determine the safety and feasibility of
administering unmatched HPDSC in conjunction with single
and double UCBTs following MAC or reduced-intensity con-
ditioning (RIC) in children and adults with malignant and
non-malignant diseases.
Methods: We developed a multicenter consortium (CCT-
HPDSC-UCBT-PI-001) to investigate this approach (Fig. 1A).
Patients with eligible malignant and non-malignant
diseases with a single CB donor product (4/6e6/6 HLA
match) and total nucleated cell dose (TNC) 5.0 x 107/kg
or double UCBT (4/6e6/6 HLA match) and combined TNC
5.0 x 107/kg are eligible. The experimental design is
depicted in Fig. 1B.
Results: Nine patients enrolled to date: six with high-risk
malignant conditions (relapsed or hypodiploid Precursor B
ALL, FLT3+ AML, T-cell ALL induction failure) and three with
non-malignant disorders (X-linked adrenoleukodystrophy,
chronic granulomatous disease, congenital amegakaryocytic
thrombocytopenia). Mean  SD CB CD34 (3.9  1.8x105/kg)
and HPDSC CD34 doses (0.3  0.15 x105/kg) (p¼0.00005)and CBT clinical trial and (B) the overall treatment plan.
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donor chimerism and 0% HPDSC was observed. Median time
to neutrophil engraftment was 22 days post UCBT (range 13-
53 days). Only one of 9 patients developed grade II AGVHD.
Seven of 9 patients are alive at 80-460 days post UCBT. One
patient died from PTLD and one from GVHD and fungal
infection.
Summary: These preliminary results suggest that single or
double UCBT combined with unrelated HPDSC infusion in
children with malignant and non-malignant diseases is safe
and well tolerated. A larger cohort and longer follow-up will
be required to determine the safety and clinical signiﬁcance
of these early ﬁndings. (NCT01586455)
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Introduction: Allogeneic stem cell transplantation (HSCT)
and immunosuppressive therapy (IST) with anti-thymocyte
globulin (ATG) are standard treatment options for a child
with aplastic anemia (AA). Response to ATG however is much
lower in developing countries.
Patients and Methods: Retrospective analysis of pediatric
patients with AA (age < 15 years) who underwent sibling
donor HSCT or received IST at Christian Medical College,
Vellore India between 1990 andMarch 2014. Fanconi anemia
was excluded with stress cytogenetics. IST consisted of either
ALG (Pasteur Merieux) for 5 days or ATGAM (Pharmacia
Upjohn) for 4 days followed by steroids and cyclosporine for
12 months. Response was assessed at 6 months after IST.
Patients undergoing HSCT used either Cy/ATG or a Fludar-
abine based regimen for conditioning.
Results: 196 children [119 males and 77 females; median
age 10.2 years (range: 2-15)] were analysed of which 119
received IST and 77 underwent HSCT. Response to IST at 6
months was 36.1% with CR in 14.3% and PR in 21.8%.
Response rates were 7.7% in children with age < 5 years,
46.6% between ages 6-10 and 43.1% between 11-15 years.
Of the 43 responders, 13(30.2%) had relapse or clonal
evolution [9 had AA, 3 had AML and 1 had MDS]. Six pa-
tients had a repeat course of ATG while another 6 under-
went BMT. The 3 year OS for the entire group is 50 + 4.7%.
Of the 77 who underwent HSCT, 12 had conditioning with
Cy/ATG, 6 had Flu/Bu/ATG and 59 had Flu/Cy + ATG or TBI
200Cg. Graft source was bone marrow in 20 and PBSC in
57. Engraftment was seen in 62 (80.5%) while 15 had either
primary graft failure or expired due to sepsis within ﬁrst 2
weeks of HSCT. Acute GVHD was seen in 32.2% of patients
and chronic GVHD in 59.6% - mostly limited. The 3 year OS
for the entire group was 71.1 + 5.2% while for a cohort of 59
patients who had Flu/Cy conditioning, the 3 yr OS was 77.6
+ 5.5%.
A Superior 3 yr OS was seen with the use of Flu/Cy con-
ditioning for HSCT compared to ATG in all age groups. It was
83.3 + 10.8 vs 15.4 + 1.2 for age< 5 yrs and 74.1 +5.7 vs 52.6 +
3.7 for age > 5 years for HSCT and ATG respectively.
Conclusion: Sibling donor allogeneic HSCT is superior to IST
across all age groups in a large cohort of Indian childrenwith
aplastic anemia. Alternative donor transplants need to beexplored in patients who do not have a HLA identical sibling
donor.297
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Pretransplant pulmonary function test (PFT) abnormalities
are correlated with risk of early respiratory failure and
mortality in adults and older children. While there is an
increasing use of allogeneic BMT in infants and young chil-
dren with metabolic and immune deﬁciency disorders, lung
function has not been systematically studied in this age
group.We describe use of forced deﬂation PFT (dPFT), a novel
technique for assessment of lung function in a series of in-
fants and young children and those unable to perform
cooperative testing.
Forced dPFT studies were coordinated with other procedures
requiring general anesthesia and performed according to
previously published techniques1. Brieﬂy, a specially con-
structed forced deﬂation device was inserted between the
endotracheal tube and anesthesia breathing circuit via a 3-
way slide valve (Figure). The lungs were inﬂated three times
to 40 cm H2O (total lung capacity) and then rapidly deﬂated
to -40 cmH2O via a pneumotachograph (to residual volume).
Raw ﬂow or volume measurements were normalized and
converted to %predicted and standard deviation scores using
data obtained in healthy children.
Between October 2008 and April 2014, 52 dPFT studies were
performed in 26 transplant recipients. Indications for BMT
were inherited metabolic disease (42%), malignancy (31%),
primary immune deﬁciency (15%) and bone marrow failure
(12%). Median age of 21 patients who had pretransplant
studies was 0.91.3 y (0.1 e 4.9 y); nine of them (43%) had
one or more prior lung diseases (respiratory failure [n¼7];
pneumonia [n¼7]; ARDS [n¼3]; bronchopulmonary
dysplasia [n¼1]; and bronchitis [n¼1]). Forced vital capacity
(FVC) and forced expiratory ﬂow (FEF75) were normal in all
but respiratory system compliance (Crs) was reduced in 5/21
cases. Six out of nine (66.7%) patients with clinical resp. is-
sues pre-BMT also had respiratory complications post-BMT
compared with 3/12 (25%) that had no pre-transplant res-
piratory issues. There were no signiﬁcant differences in pre-
transplant FVC, FEF75 and Crs between those patients who
did and who did not have post-transplant pulmonary com-
plications with median follow-up of 1.71.5 y (p¼0.435,
p¼0.305, and p¼0.301 respectively). There were no compli-
cations during the procedures and dPFT studies could be
safely done in coordination with other procedures requiring
anesthesia.
In this pilot study, pre-transplant PFTs were not predictive of
post-transplant pulmonary complications, and most patients
had normal volume and ﬂows. A larger study would be
required to determine prevalence and signiﬁcance of lung
function abnormalities in infants and toddlers undergoing
transplantation.
